보고서 요약(국문)

개요
세계 세기관지염 치료 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
세기관지염은 어린아이들에게 흔히 발생하는 하기도 감염으로, 주로 호흡기 세포융합 바이러스(RSV)와 같은 바이러스 감염이 원인입니다. 세기관지염은 일반적으로 증상 완화와 아이에게 충분한 산소와 수분을 공급하는 대증 요법으로 치료합니다. 세기관지염은 대개 경미한 질병이지만, 심한 경우 폐부전으로 이어질 수 있습니다.
2세 미만 영유아에게 가장 흔한 하기도 감염은 세기관지염입니다. 세기관지염을 유발하는 바이러스는 접촉을 통해 전파됩니다. 침이나 입술 또는 코의 점액은 이러한 바이러스가 전파될 수 있는 호흡기 비말입니다. 이러한 비말은 공기 중에 떠다니며 재채기나 기침을 할 때 사람 간에 전파되거나, 자주 만지는 물건이나 표면에 달라붙을 수 있습니다.
시장 동향: 성장 동인 및 제약 요인
호흡기 세포융합 바이러스(RSV) 감염 증가
호흡기 세포융합 바이러스(RSV)는 세기관지염의 가장 흔한 원인입니다. RSV는 호흡기, 특히 세기관지 또는 작은 기도에 영향을 미치는 전염성이 매우 높은 바이러스로, 부종과 울혈을 유발합니다. 신생아와 어린아이들이 세기관지염에 걸리는 주요 원인입니다. 세기관지염 치료 시장 성장을 견인하는 주요 요인 중 하나는 RSV 감염 증가입니다.
예를 들어, 미국 의학 협회(AMA)에 따르면 미국에서는 매년 5세 미만 어린이 약 230만 명이 RSV로 인해 외래 진료(입원하지 않음)를 받고, 약 5만 8천~8만 명이 입원합니다. 계절성 호흡기 바이러스, 특히 세기관지염의 주요 원인인 호흡기 세포융합 바이러스(RSV)의 유행은 시장에 상당한 영향을 미칠 수 있습니다. 유행 기간 동안 진단 장비, 항바이러스제, 보조 치료 용품에 대한 수요가 증가합니다. 바이러스 감염을 식별하는 신속 진단 검사 개발과 같은 의료 기술의 발전으로 세기관지염의 진단 및 관리가 개선되었습니다. 혁신적인 의료 치료법과 제품은 시장 확대를 촉진할 잠재력을 가지고 있습니다.
시장 동향: 제약 요인
세기관지염 시장은 여러 가지 제약 요인에 의해 제약을 받을 수 있습니다. 이러한 요소들은 시장 발전을 저해하고 치료법 및 관련 제품의 도입, 개발 및 마케팅에 영향을 미칠 수 있습니다. 예를 들어, 세기관지염에 특화된 항바이러스제는 많지 않습니다. 특히 모든 환자에게 효과적인 약물이 부족한 상황에서 맞춤형 치료의 부재는 시장 확대를 저해할 수 있습니다. 또한, 중증 세기관지염의 경우 입원, 의료 장비 및 보조 치료에 상당한 비용이 발생할 수 있습니다. 높은 치료 비용은 시장 확장을 저해하고 특히 개발도상국에서 의료 접근성을 제한할 수 있습니다.
세분화 분석
전 세계 세기관지염 치료 시장은 질병 유형, 치료법, 연령대, 판매 채널 및 지역별로 세분화됩니다.
유형별 세기관지염 세그먼트 중 폐쇄성 세기관지염 세그먼트는 세기관지염 치료 유형 시장 점유율의 약 41.7%를 차지했습니다.
폐쇄성 세기관지염 또는 수축성 세기관지염이라고도 하는 심각한 폐 질환인 폐쇄성 세기관지염은 폐의 미세한 기도(세기관지)에 염증과 흉터가 생기는 질환입니다. 이 질환으로 인해 기도가 점진적으로 좁아지고 막히면서 공기가 폐로 들어가고 나가는 것이 점점 어려워집니다.
폐쇄성 세기관지염에 대한 효과적인 치료법을 개발하기 위해서는 연구가 필수적입니다. 의학적 개입을 발전시키고 환자들의 삶의 질을 향상시키기 위해서는 질병의 기전을 이해하고, 바이오마커를 발견하며, 유망한 치료 표적을 연구하는 것이 필수적입니다. 따라서 폐쇄성 세기관지염에 대한 연구 및 개발의 증가는 이러한 목표 달성에 도움이 됩니다.
이처럼 폐쇄성 세기관지염에 대한 연구 및 개발의 증가는 해당 시장의 성장을 촉진합니다. 예를 들어, 2023년 5월, Zambon은 폐쇄성 세기관지염 환자를 대상으로 흡입용 리포좀 사이클로스포린 A(L-CsA-i)를 평가하는 3상 임상 개발 프로그램의 환자 등록을 완료했습니다. 이 회사는 중요한 임상 시험의 환자 등록 완료를 통해 전 세계 폐쇄성 세기관지염 환자들에게 절실히 필요한 치료법을 제공하고자 하는 목표에 한 걸음 더 다가섰습니다. 이처럼 앞서 언급한 요인들이 해당 시장의 성장을 견인하고 있습니다.

지리적 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
현재 북미는 시장 점유율과 매출 측면에서 세기관지염 치료제 시장을 주도하고 있으며, 이러한 지배력은 향후 더욱 강화될 것으로 예상됩니다. 이는 주요 경쟁업체의 존재와 의료비 지출 증가로 인한 해당 지역 시장의 빠른 성장세에 기인합니다. 또한, 정부 및 의료 기관의 제품 승인 증가도 북미 지역의 시장 성장을 뒷받침하고 있습니다.
예를 들어, 2023년 7월 17일, 부모들은 매년 미국에서 1세 미만 영유아의 최대 3%를 입원시키는 흔한 질병인 호흡기 세포융합 바이러스(RSV)로부터 자녀를 보호할 수 있는 새로운 장기 지속형 약물을 이용할 수 있게 되었습니다. 미국 식품의약국(FDA)은 신생아 및 RSV 유행 시기에 태어났거나 RSV 유행 시기에 접어드는 영유아의 RSV 예방을 위해 베이포르투스(니르세비맙-알립)를 승인했습니다.

또한, 아시아 태평양 지역은 염증성 호흡기 질환의 유병률 증가로 인해 예측 기간 동안 성장세를 보일 것으로 예상됩니다. 이 지역의 시장 성장률은 의료 인프라 개발에 힘입어 더욱 가속화될 것입니다.
코로나19 영향 분석
코로나19 대유행 시기에는 코로나19 환자 급증에 대응하기 위해 의료 자원이 재배치되었습니다. 병원 및 의료기관의 과밀화로 인해 세기관지염 환자에게 최상의 치료를 제공하기 어려웠습니다. 의료진, 병상, 의료 장비 등의 자원이 코로나19 환자에게 우선적으로 제공되었습니다.
많은 부모와 보호자들은 자녀를 바이러스에 노출시킬 것을 우려하여 병원이나 의원 방문을 꺼렸습니다. 이러한 주저함은 세기관지염 및 코로나19와 무관한 다른 질환으로 인한 입원 건수를 감소시켜 세기관지염 치료제 수요에 영향을 미쳤습니다.
코로나19에 감염되었던 일부 어린이들은 호흡기 문제를 지속적으로 겪었습니다. 이는 세기관지염과 유사한 증상과 같은 잠재적인 장기적인 호흡기 문제에 대한 우려를 불러일으켰으며, 이는 향후 세기관지염 치료제 시장에 영향을 미칠 수 있습니다.
시장 세분화
질병 유형별
• 바이러스성 세기관지염
• 폐쇄성 세기관지염
치료법별
• 약물
o 항염증제
o 항생제
o 기관지 확장제
o 점액용해제
o 기타
• 산소 요법
• 기타
연령대별
• 유아
• 영유아
• 성인
판매 채널별
• 유통 채널
o 병원 약국
o 온라인 약국
o 소매 약국
• 최종 사용자
o 병원
o 전문 클리닉
o 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 업체 시장의 주요 글로벌 기업으로는 사노피, 글락소스미스클라인, 타지 파마슈티컬스, 아발론 파마, 아스트라제네카, 마일란, 이노젠, 인바케어, CAIRE, 드라이브 드빌비스 인터내셔널 등이 있습니다.
주요 개발 사항
• 2023년 1월 5일, 니르세비맙의 생물학적 제제 허가 신청(BLA)이 미국 식품의약국(FDA) 의약품 평가연구센터(CDER)에서 승인되었습니다. 니르세비맙은 두 번째 호흡기세포융합바이러스(RSV) 유행 기간 동안 중증 RSV 질환 발병 위험이 있는 24개월 미만 영유아와 첫 번째 RSV 유행 기간에 접어들거나 현재 유행 중인 신생아 및 영유아의 치료에 사용됩니다.

• 2022년 8월 25일, 화이자(Pfizer Inc.)는 이가 RSV 프리퓨전 F 백신 후보 물질인 RSVpreF와 관련하여 3상 임상시험(NCT05035212) RENOIR(RSV 백신 효능 연구, RSV 질환에 대한 고령자 면역)에서 긍정적인 주요 결과를 발표했습니다.

보고서 구매 이유:

• 질병 유형, 치료법, 연령대, 판매 채널 및 지역별 글로벌 세기관지염 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 세기관지염 치료 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료를 제공합니다.

글로벌 세기관지염 치료 시장 보고서는 약 69개의 표, 63개의 그림, 그리고 177페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Bronchiolitis Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Bronchiolitis is a common lower respiratory tract infection that affects young children, often caused by a viral infection, most commonly respiratory syncytial virus (RSV). Bronchitis is often treated with supportive care that focuses on symptom relief and making sure the child gets enough oxygen and fluids. Although bronchiolitis typically only causes a minor illness, severe cases can lead to lung failure.
The most typical lower respiratory tract infection in children under the age 2 is bronchiolitis. The bronchiolitis-causing viruses are spread by contact. Saliva or mucus from the lips or nose are respiratory droplets that these viruses can transmit through. These droplets are airborne and spread from person to person when someone sneezes or coughs, or they can attach to frequently touched items or surfaces.
Market Dynamics: Drivers and Restraints
The rising incidence of respiratory syncytial virus (RSV)
The respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis. RSV is a highly contagious virus that affects the respiratory system, specifically the bronchioles or small airways, causing swelling and congestion. It is the main reason why newborns and young children get bronchiolitis. One of the main factors propelling the market for bronchiolitis treatment is the rising incidence of respiratory syncytial virus (RSV) infection.
For instance, according to American Medical Association, stated that each year in United States, RSV leads to approximately 2.3 million outpatient (non-hospitalization) visits among children younger than 5 years old and about 58,000-80,000 hospitalizations among children younger than 5 years old.
Seasonal respiratory virus outbreaks, especially respiratory syncytial virus (RSV), a prominent cause of bronchiolitis, can also have a considerable effect on the market. The need for diagnostic equipment, antiviral drugs, and supportive care goods rises during outbreaks. The diagnosis and management of bronchiolitis have improved because to developments in medical technology, such as the creation of quick diagnostic tests to identify viral infections. Innovative medical treatments and products have the potential to expand markets.
Market Dynamics: Restraint
The bronchiolitis market may be constrained by a number of conflicts. These elements may hinder the development of the market and have an impact on the adoption of treatments and related products as well as their development and marketing. For instance, there aren't many antiviral medications specifically for bronchiolitis. Particularly in the absence of pharmaceuticals that are universally beneficial, the lack of tailored therapy can impede market expansion. Furthermore, hospitalisation, medical equipment, and supportive care might come at a high expense in situations of severe bronchiolitis. High treatment costs can impede market expansion and restrict access to healthcare, particularly in developing countries.
Segment Analysis
The global bronchiolitis treatment market is segmented based on disease type, treatment, age group, sales channel and region.
The bronchiolitis obliterans segment from the type segment accounted for approximately 41.7% of bronchiolitis treatment type share
The severe lung condition bronchiolitis obliterans, also known as obliterative bronchiolitis or constrictive bronchiolitis, is defined by inflammation and scarring of the tiny airways in the lungs (bronchioles). It becomes more difficult for air to enter and exit the lungs as a result of the condition's gradual constriction and obstruction of these airways.
For the purpose of creating efficient cures and treatments for bronchiolitis obliterans, research is vital. To advance medical interventions and enhance the quality of life for those who are affected, it is essential to comprehend the illness mechanisms, discover biomarkers, and investigate prospective therapeutic targets. Therefore, the increase of study and developments on bronchiolitis obliterans helps.
Thus rise of research and developments on bronchiolitis obliterans helps to boost the segment growth. For instance, In May 2023, Zambon completes enrollment in the Phase 3 Clinical Development Programme evaluating liposomal cyclosporine A for inhalation (L-CsA-i) in BOS patients. The company's aim of providing a much needed therapy to lung transplant recipients globally with BOS is one step closer with the conclusion of enrolment in the company's crucial trials. Thus, the aforementioned factors boost segment expansion.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America currently controls the market for bronchiolitis drugs in terms of market share and revenue, and this dominance will only increase during the anticipated time period. This is owing to the presence of large key competitors and the fact that the market in that region will continue to expand quickly as a result of rising healthcare expenditures. Additionally, the region's expansion is supported by the rise in product approvals by governmental or medical agencies.
For instance, on July 17, 2023, parents currently had a new long-acting drug to protect their children against respiratory syncytial virus (RSV), a common germ that hospitalizes as many as 3% of children under the age of 1 in the United States each year. The U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of RSV in newborns and infants born during or entering their first RSV season.
In addition, Asia-Pacific will be growing over the projection period due to the region's rising prevalence of inflammatory respiratory diseases. The growth rate of the market in this region will also be further accelerated by the development of the healthcare infrastructure.
COVID-19 Impact Analysis
Healthcare resources were redirected to handle a rise in COVID-19 cases at the height of the COVID-19 epidemic. The overcrowding in hospitals and healthcare institutions made it difficult to provide patients with bronchiolitis with the best care possible. For COVID-19 patients, resources like medical personnel, hospital beds, and medical equipment were given priority.
For fear of exposing their kids to the virus, many parents and other carers were reluctant to bring their kids to clinics and hospitals. This hesitation reduced hospital admissions for bronchiolitis and other disorders unrelated to COVID-19, which had an effect on the demand for therapies for bronchiolitis.
Some kids who had COVID-19 continued to have respiratory issues. This sparked worries about potential long-term respiratory problems, such as symptoms similar to bronchiolitis, which may have an effect on the market for bronchiolitis therapies in the future.
Market Segmentation
By Disease Type
• Viral bronchiolitis
• Bronchiolitis obliterans
By Treatment
• Medication
o Anti-Inflammatory Drugs
o Antibiotics
o Bronchodilators
o Mucolytic
o Others
• Oxygen Therapy
• Others
By Age Group
• Young children
• Infants
• Adults
By Sales Channel
• Distribution Channel
o Hospital Pharmacies
o Online Pharmacies
o Retail Pharmacies
• End-Users
o Hospitals
o Specialty Clinics
o Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Sanofi, GlaxoSmithKline Inc, Taj Pharmaceuticals Limited, Avalon Pharma Private Limited, AstraZeneca, Mylan N.V., Inogen, Inc, Invacare Corporation, CAIRE Inc, Drive DeVilbiss International and among others.
Key Developments
• On January 5, 2023, Biologics Licence Application (BLA) for nirsevimab had been approved by the U.S. Food and Drug Administration (FDA) Centre for Drug Evaluation and Research (CDER) for the treatment of children up to 24 months old who are still susceptible to developing severe respiratory syncytial virus (RSV) disease during the second RSV season as well as for newborns and infants entering or currently undergoing their first RSV season.
• On August 25, 2022, regarding its bivalent RSV prefusion F vaccine candidate, RSVpreF, Pfizer Inc. published beneficial top-line data from the Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunised against RSV disease).
Why Purchase the Report?
• To visualize the global bronchiolitis treatment market segmentation based on disease type, treatment, age group, sales channel and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of bronchiolitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global bronchiolitis treatment market report would provide approximately 69 tables, 63 figures and 177 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment
3.3. Snippet by Age Group
3.4. Snippet by Sales Channel
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising incidence of respiratory syncytial virus (RSV)
4.1.1.2. Increasing product approvals
4.2. Restraints
4.2.1.1. Expensive cost associated with the research and development
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Viral bronchiolitis *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bronchiolitis obliterans
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Medication *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Anti-Inflammatory Drugs
8.2.4. Antibiotics
8.2.5. Bronchodilators
8.2.6. Mucolytic
8.2.7. Others
8.3. Oxygen Therapy
8.4. Others
9. By Age Group
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.1.2. Market Attractiveness Index, By Age Group
9.2. Young children*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Infants
9.4. Adults
10. By Sales Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.1.2. Market Attractiveness Index, By Sales Channel
10.2. Distribution Channel*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Hospital Pharmacies
10.2.4. Online Pharmacies
10.2.5. Retail Pharmacies
10.3. End-Users
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.3.3. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Sanofi *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. GlaxoSmithKline Inc
13.3. Taj Pharmaceuticals Limited
13.4. Avalon Pharma Private Limited
13.5. AstraZeneca
13.6. Mylan N.V.
13.7. Inogen, Inc
13.8. Invacare Corporation
13.9. CAIRE Inc
13.10. Drive DeVilbiss International
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Sanofi, 4.	Key Developments, GlaxoSmithKline Inc, Taj Pharmaceuticals Limited, Avalon Pharma Private Limited, AstraZeneca, Mylan N.V., Inogen, Inc, Invacare Corporation, CAIRE Inc, Drive DeVilbiss International

표 목록 (Tables)

List of Tables

Table 1 Global Bronchiolitis Treatment Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Bronchiolitis Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Bronchiolitis Treatment Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Bronchiolitis Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Bronchiolitis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Bronchiolitis Treatment Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Bronchiolitis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 8 Global Bronchiolitis Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Bronchiolitis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 10 Global Bronchiolitis Treatment Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Bronchiolitis Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 12 Global Bronchiolitis Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Bronchiolitis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 14 Global Bronchiolitis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Bronchiolitis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Bronchiolitis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 17 North America Bronchiolitis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 18 North America Bronchiolitis Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 19 North America Bronchiolitis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 20 North America Bronchiolitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Bronchiolitis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 22 South America Bronchiolitis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 23 South America Bronchiolitis Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 24 South America Bronchiolitis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 25 South America Bronchiolitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Bronchiolitis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 27 Europe Bronchiolitis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 28 Europe Bronchiolitis Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 29 Europe Bronchiolitis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 30 Europe Bronchiolitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Bronchiolitis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Bronchiolitis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Bronchiolitis Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Bronchiolitis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Bronchiolitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Bronchiolitis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Bronchiolitis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Bronchiolitis Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Bronchiolitis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 40 Sanofi: Overview

Table 41 Sanofi: Product Portfolio

Table 42 Sanofi: Key Developments

Table 43 GlaxoSmithKline Inc: Overview

Table 44 GlaxoSmithKline Inc: Product Portfolio

Table 45 GlaxoSmithKline Inc: Key Developments

Table 46 Taj Pharmaceuticals Limited: Overview

Table 47 Taj Pharmaceuticals Limited: Product Portfolio

Table 48 Taj Pharmaceuticals Limited: Key Developments

Table 49 Avalon Pharma Private Limited: Overview

Table 50 Avalon Pharma Private Limited: Product Portfolio

Table 51 Avalon Pharma Private Limited: Key Developments

Table 52 AstraZeneca: Overview

Table 53 AstraZeneca: Product Portfolio

Table 54 AstraZeneca: Key Developments

Table 55 Mylan N.V.: Overview

Table 56 Mylan N.V.: Product Portfolio

Table 57 Mylan N.V.: Key Developments

Table 58 Inogen, Inc: Overview

Table 59 Inogen, Inc: Product Portfolio

Table 60 Inogen, Inc: Key Developments

Table 61 Invacare Corporation: Overview

Table 62 Invacare Corporation: Product Portfolio

Table 63 Invacare Corporation: Key Developments

Table 64 CAIRE Inc: Overview

Table 65 CAIRE Inc: Product Portfolio

Table 66 CAIRE Inc: Key Developments

Table 67 Drive DeVilbiss International: Overview

Table 68 Drive DeVilbiss International: Product Portfolio

Table 69 Drive DeVilbiss International: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Bronchiolitis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Bronchiolitis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 4 Global Bronchiolitis Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 5 Global Bronchiolitis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 6 Global Bronchiolitis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Bronchiolitis Treatment Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 8 Viral bronchiolitis Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Bronchiolitis obliterans Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Global Bronchiolitis Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 11 Medication Treatment in Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Oxygen Therapy Treatment in Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Others Treatment in Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Global Bronchiolitis Treatment Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 15 Young children Age Group in Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Infants Age Group in Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Global Bronchiolitis Treatment Market Y-o-Y Growth, By Sales Channel, 2022-2030 (%)

Figure 18 Distribution Channel Sales Channel in Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 End-Users Sales Channel in Global Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Bronchiolitis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 South America Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 North America Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 North America Bronchiolitis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 28 North America Bronchiolitis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 29 North America Bronchiolitis Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 30 North America Bronchiolitis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 31 North America Bronchiolitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 33 South America Bronchiolitis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 34 South America Bronchiolitis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 35 South America Bronchiolitis Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 36 South America Bronchiolitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 37 Europe Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 38 Europe Bronchiolitis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 39 Europe Bronchiolitis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 40 Europe Bronchiolitis Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 41 Europe Bronchiolitis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 42 Europe Bronchiolitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 44 Asia-Pacific Bronchiolitis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 45 Asia-Pacific Bronchiolitis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 46 Asia-Pacific Bronchiolitis Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 47 Asia-Pacific Bronchiolitis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 48 Asia-Pacific Bronchiolitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 49 Middle East & Africa Bronchiolitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 50 Middle East & Africa Bronchiolitis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 51 Middle East & Africa Bronchiolitis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 52 Middle East & Africa Bronchiolitis Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 53 Middle East & Africa Bronchiolitis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 54 Sanofi: Financials

Figure 55 GlaxoSmithKline Inc: Financials

Figure 56 Taj Pharmaceuticals Limited: Financials

Figure 57 Avalon Pharma Private Limited: Financials

Figure 58 AstraZeneca: Financials

Figure 59 Mylan N.V.: Financials

Figure 60 Inogen, Inc: Financials

Figure 61 Invacare Corporation: Financials

Figure 62 CAIRE Inc: Financials

Figure 63 Drive DeVilbiss International: Financials

세계 세기관지염 치료 시장 – 2023-2030

Global Bronchiolitis Treatment Market - 2023-2030